Core Viewpoint - The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the 2mg/kg every-4-weeks dosing regimen of pegunigalsidase alfa for adult patients with Fabry disease, pending review by the European Commission, with a decision expected by March 2026 [1] Group 1: Company Updates - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the positive CHMP opinion, which aims to reduce the treatment burden for patients and their families by extending the time between infusions [2] - Protalix is eligible for a $25 million regulatory milestone payment from Chiesi if the new dosing regimen is approved by the European Commission [2] Group 2: Product Information - Pegunigalsidase alfa is intended for adult patients with Fabry disease who are stable on enzyme replacement therapy, and the positive opinion follows a re-examination of the dosing regimen application [1][2] - The CHMP's opinion is based on results from the BRIGHT study, which assessed the safety, efficacy, and pharmacokinetics of the alternative dosing regimen over 52 weeks [2] Group 3: Industry Context - Fabry disease is a rare inherited lysosomal storage disorder caused by mutations in the GLA gene, leading to serious health complications, including kidney failure and heart issues [3] - Early detection and access to appropriate treatments are critical for managing symptoms and slowing disease progression in Fabry disease [3]

Core Viewpoint - The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of a new dosing regimen for Elfabrio (pegunigalsidase alfa) for the treatment of Fabry disease, which, if approved by the European Commission, would significantly reduce the treatment burden for patients and their families [1][2]. Company Updates - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the positive CHMP opinion for the 2 mg/kg every-four-weeks (E4W) dosing regimen for Elfabrio, aimed at adult patients with Fabry disease who are stable on enzyme replacement therapy [1][2]. - Protalix is set to receive a regulatory milestone payment of $25 million from Chiesi if the E4W dosing regimen is approved by the European Commission [3]. Product Information - Elfabrio is a PEGylated enzyme replacement therapy designed to treat Fabry disease, utilizing a plant cell culture-expressed and chemically modified version of the α-Galactosidase-A enzyme [4]. - Clinical studies have shown that Elfabrio has an initial half-life of 78.9 ± 10.3 hours, indicating stable pharmacokinetic parameters [4]. Clinical Study Insights - The CHMP's positive opinion is based on results from the BRIGHT study, which assessed the safety, efficacy, and pharmacokinetics of the new dosing regimen over 52 weeks, along with an ongoing open-label extension study [2]. - The updated Population Pharmacokinetics model and exposure–response analysis further support the new dosing regimen, leveraging data from multiple clinical studies [2]. Industry Context - The approval of the new dosing regimen is seen as a critical step in expanding treatment options for patients with Fabry disease, addressing both effective management of the condition and patient preferences to minimize disruptions in daily life [2]. - The collaboration between Chiesi and Protalix highlights the commitment to advancing treatments for rare diseases, with a focus on innovative therapeutic solutions [2][19].

Core Viewpoint - Chiesi Global Rare Diseases and Protalix BioTherapeutics have requested a re-examination of the negative opinion from the CHMP regarding the proposed dosing regimen for Elfabrio® (pegunigalsidase alfa) [1][2] Company Overview - Chiesi Global Rare Diseases is a business unit of the Chiesi Group, focused on delivering innovative therapies for rare diseases [16] - Protalix BioTherapeutics specializes in developing recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx [18] Product Information - Elfabrio® is indicated for the treatment of adults with confirmed Fabry disease [3] - The current approved dosing regimen is 1 mg/kg every 2 weeks, while a new regimen of 2 mg/kg every 4 weeks is under review [2] Clinical Trial Insights - In clinical trials, 14% of patients treated with Elfabrio experienced hypersensitivity reactions, with 3% experiencing anaphylaxis [6] - Infusion-associated reactions were reported in 29% of patients, including symptoms such as nausea, chills, and rash [7][9] Regulatory Context - The existing marketing authorization for Elfabrio remains effective while the re-examination process is ongoing [2] - The outcome of the re-examination will influence the final decision by the European Commission [2] Disease Background - Fabry disease is a rare inherited lysosomal storage disorder caused by mutations in the GLA gene, leading to enzyme deficiency and accumulation of globotriaosylceramide (GL-3) [11][12] - Symptoms include fatigue, chronic pain, and increased risk of serious complications such as kidney failure and stroke [11][12]

Core Insights - Chiesi Global Rare Diseases and Protalix BioTherapeutics received a negative opinion from the CHMP of the EMA regarding the approval of a new dosing regimen for Elfabrio (pegunigalsidase alfa) [1][2] - The proposed regimen of 2 mg/kg every 4 weeks was not deemed to have sufficient efficacy compared to the currently approved regimen of 1 mg/kg every 2 weeks [1][2] Company Overview - Chiesi Global Rare Diseases is a unit of the Chiesi Group focused on innovative therapies for rare diseases [1][16] - Protalix BioTherapeutics specializes in developing recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system [1][19] - Both companies are committed to reducing the treatment burden for patients with Fabry disease [2][20] Clinical Trial Insights - The CHMP review was based on data from the BRIGHT trial and its extension study, which had a median exposure of almost six years [2] - The data from these studies, along with modeling and exposure-response analyses from prior trials, were insufficient to demonstrate similar efficacy for the new dosing regimen [2] Fabry Disease Context - Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, leading to serious health complications [11][12] - Early detection and access to treatment are critical for managing symptoms and slowing disease progression [12] Safety Information - Elfabrio is indicated for adults with confirmed Fabry disease and has been associated with hypersensitivity reactions, including anaphylaxis [3][4] - In clinical trials, 14% of patients experienced hypersensitivity reactions, with 3% experiencing anaphylaxis [6][9]

Company Overview - Protalix BioTherapeutics, Inc. is a New Jersey-based biopharmaceutical company specializing in recombinant therapeutic proteins [4] - The company develops innovative plant-based biologics, including products like Elelyso, Elfabrio, PRX-115, and PRX-119 [4] Investment Activity - Goldman Sachs Group Inc. increased its holdings in Protalix BioTherapeutics by 482.3% during the first quarter, acquiring 239,751 shares, bringing its total ownership to 289,461 shares valued at approximately $741,000 [1] Product Development - Protalix is expanding its ProCellEx platform into drug delivery optimization, targeting specific tissue requirements, which is considered a "game-changer" for the company [3] - The ProCellEx platform is noted for its cost efficiency and ability to express complex protein capabilities, positioning it as a leader in future biopharmaceutical developments [3] Market Position - The company is recognized as a hidden penny stock with potential for growth, likened to planting a tree that requires time and patience to flourish [2]

Company Overview - Protalix BioTherapeutics (PLX) is a biotechnology company that has two marketed therapies: Elelyso for Gaucher disease and Elfabrio for Fabry Disease [1] - The company is actively developing a clinical pipeline that may present future opportunities [1] Market Position - The presence of two marketed therapies positions Protalix BioTherapeutics as a player in the biotechnology sector focused on rare diseases [1]